linjc16/ctgov huggingface dataset:
Intraoperative Electrical Impedance Tomography in Obese Patients Undergoing Robotic Assisted Radical Prostatectomy.

Study Overview
=================
Brief Summary
-----------------
The primary objective of our study will be verify a possible improvement in arterial oxygenation in the obese patient undergoing robotic-assisted radical prostatectomy if the ventilation will be guided by electrical impedance tomography rather than peripheral saturation alone.

Official Title
-----------------
Optimization of Intraoperative Ventilation Guided by Electrical Impedance Tomography in Combination With Oxygen Saturation by Pulse Oximetry (SpO2) Versus SpO2 Alone in Obese Patients Undergoing Robotic Assisted Radical Prostatectomy: Prospective Randomized Trial

Conditions
-----------------
Obese

Intervention / Treatment
-----------------
* Device: Electrical Impedance Tomography
* Device: Peripheral arterial Saturation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for laparoscopic radical prostatectomy BMI ≥ 30 kg/m2 Exclusion Criteria: surgery duration < 2 hours history of lung diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electrical Impedance Tomography<br>patient monitored by Electrical Impedance Tomography | Device: Electrical Impedance Tomography<br>* In 27 patients ventilation will be guided with an Electrical Impedance Tomography system<br>|
| Active Comparator: Peripheral arterial Saturation<br>patient monitored by Peripheral arterial Saturation alone | Device: Peripheral arterial Saturation<br>* The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The arterial oxygen pressure / fraction of inspired oxygen (pO2 /FiO2) ratio | The primary outcome will be the ratio of arterial oxygen pressure and the fraction of inspired oxygen (pO2 / FiO2 ratio) at the end of the intervention, detected by blood gas analysis. | 16 months |
Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine which drug makes lower intraocular pressure

Detailed Description
-----------------
Increase in intraocular pressure (IOP) following tracheal intubation during general anesthesia can be troublesome. The investigators compared the influence of cisatracurium and atracurium on IOP in patients undergoing general anesthesia.

Official Title
-----------------
Study of Effects of Cisatracurium and Atracurium on Intraocular Pressure

Conditions
-----------------
Intraocular Pressure

Intervention / Treatment
-----------------
* Drug: atracurium
* Drug: cisatracurium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA class of I or II baseline IOP of lower than 20 mmHg stable hemodynamics no history of ophthalmic diseases not using drugs affecting IOP (e.g. anticholinergics, sympathomimetics) no contraindication for atracurium or cisatracurium administration. Exclusion Criteria: difficulty in mask ventilation or in tracheal intubation end expiratory CO2 of below 35 mmHg or over 45 mmHg O2 saturation of below 90%
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: atracurium<br>Patients who underwent general anesthesia received atracurium | Drug: atracurium<br>* atracurium, Drop,0.5 mg/kg, one time, one day<br>|
| Other: cisatracurium<br>Patients who underwent general anesthesia received cisatracurium | Drug: cisatracurium<br>* cisatracurium, drop,0.15mg/kg,one time, one day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraocular pressure | determining intraocular pressure in atracurium and cisatracurium groups | at 2 minutes after intubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| systolic blood pressure | identification of systolic blood pressure in atracurium and cisatracurium groups | at 2 minutes after intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intraocular pressure, anesthesia,cisatracurium,atracurium.
Role of Intrauterine Insemination in Patients With Endometriosis I-II

Study Overview
=================
Brief Summary
-----------------
Intrauterine insemination (IUI) is an ART that provides good results in selected patients, improving their reproductive prognosis. Endometriosis I y II, according to ASRM classification, remains an indication to perform IUI. This indication is on continuous debate, considering that different studies have shown controversial results about it, due to the poor reproductive outcomes in this group of patients

Official Title
-----------------
Role of Intrauterine Insemination in Patients With Endometriosis I-II

Conditions
-----------------
Endometriosis I-II

Intervention / Treatment
-----------------
* Procedure: Intrauterine insemination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:< 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated - Exclusion Criteria: > 38 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endometriosis I y II, according to ASRM classification<br>Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated | Procedure: Intrauterine insemination<br> <br> |
| patients without endometriosis<br>Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated | Procedure: Intrauterine insemination<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate | to compare pregnancy rate between Endometriosis I-II patients (according to ASRM classification) vs. control group (patients without endometriosis) going under an IUI cycle | 2011-2017 |
Prospective Validation of the CoDE-HF Algorithm for the Diagnosis of Acute Heart Failure

Study Overview
=================
Brief Summary
-----------------
Acute heart failure is a life-threatening condition where the heart is suddenly unable to pump blood around the body. It can be challenging to diagnose because the symptoms often mimic other conditions. Previous studies have showed that delays in making the correct diagnosis result in worse outcomes. We therefore developed a decision-support tool called CoDE-HF that uses a computer algorithm to combine levels of a blood test called NT-proBNP with patient factors to calculate the probability of acute heart failure for an individual. In this project, we wish to evaluate the performance of CoDE-HF in approximately 2,000 patients attending the Emergency Department with suspected acute heart failure. We will store surplus material from their blood tests to measure NT-proBNP and link information from their electronic health records with other routinely collected medical information in regional and national databases in order to evaluate this algorithm.

Official Title
-----------------
Prospective Validation of the CoDE-HF Algorithm for the Diagnosis of Acute Heart Failure

Conditions
-----------------
Acute Heart Failure, Diagnosis

Intervention / Treatment
-----------------
* Diagnostic Test: CoDE-HF decision support tool


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting to the Emergency Department with acute breathlessness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CoDE-HF decision support tool|We will assess the diagnostic performance of the CoDE-HF decision support tool|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adjudicated diagnosis of acute heart failure |  | At index presentation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subsequent hospitalisation with heart failure |  | 3 months | 
| All-cause death |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Artificial Intelligence
Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Correlation between Idiopathic Parkinson's disease and diabetes mellitus in Egyptian Elderly Patients

Detailed Description
-----------------
Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score difference between Group 1 and Group 2 . Oral glucose tolerance test will be performed and compared between Group 3 and Group 4. Association between glucose level and motor complication of L-dopa among Idiopathic Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS).

Official Title
-----------------
Investigation of the Possible Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Elderly Patients

Conditions
-----------------
Observation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic Patients Idiopathic Parkinsonism Exclusion Criteria: Secondary Parkinsonism due to stroke, trauma and encephalitis. Drug induced Parkinsonism.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Idiopathic Parkinson's<br>Oral glucose tolerance test The Unified Parkinson's Disease Rating Scale (UDPRS). | |
| Diabetics receive sulphonylurea group<br>Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score | |
| Diabetics on sulphonylurea and metformin<br>Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score | |
| Healthy<br>Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score Oral glucose tolerance test | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| UPDRS (Unified Parkinson's Disease Rating) Scale) | Association between glucose level and motor complication of L-dopa among Idiopathic , , Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS)., high scores mean worsen condition | Baseline | 
| Oral Glucose Tolerance Test | Between Idiopathic Parkinson's patients and the Control group | 0, 0.5 hour , 1 hour, 1.5 hour , 2 hour | 
| RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) | among Diabetic Patients, total score 13 , high scores mean worsen condition | Baseline |
Validation of the French Version of the Fatigue Score Brief Fatigue Inventory ( BFI).

Study Overview
=================
Brief Summary
-----------------
Fatigue, or asthenia, is an important symptom for the diagnosis and follow-up of patients in routine as well as research oriented clinical practice. Various questionnaires measuring fatigue have been developed, but few have been validated in french. MFI (Multidimensional Fatigue Inventory) has been validated in french in only one study. BFI (Brief Fatigue Inventory) has been translated but never validated in french language. The main purpose of this study is to validate psychometrically the french version of BFI.

Official Title
-----------------
Validation de la Version française du Score de Fatigue  Brief Fatigue Inventory (BFI)

Conditions
-----------------
Fatigue Symptom

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consultation for fatigue as symptôme principal ( isolated or asociated with other symptomes). Exclusion Criteria: Pregnancy Psychosis. Unable to complete questionnaire Phsyiological fatigue due to effort and reversible rest. Post-traumatic stress disorder -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 9 points of BFI, each of them between 0 to 10. of BFI |  | 3 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fatigue, Brief Fatigue Inventory (BFI), Primary care, General Practitioners
Paperless Parotograph in Evaluation of Labour

Study Overview
=================
Brief Summary
-----------------
Using Paperless partograph management of labour as simple tool to prevent obstructed labour or prolonged labour or its complications at the mother or her fetus

Detailed Description
-----------------
WHO PARTOGRAPH is very work load need more time and more stuff in both treaning and learning for plotting and for drowning but inside labour room needing simple partograph playing the simple partograph beast role in management of labour and stand test against time for saving live of labour women and her child Paperless parotograph can help obestitricianes to talk decision about when to transferr the labourus women to higher centers on to make medical intervention or what time to end labour by caesarian section

Official Title
-----------------
Paperless Partograph Evaluation of Labour

Conditions
-----------------
Labor Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women ln active phase of labour With single pregnanncy living fetus cephalic presentation occipt anterior 36 weak gestional age up to full term Exclusion Criteria: preterm . .or women with antipartum hemorrhage . or multipregnanncy previous utrine surgery or abnormal cardiotocograph(CTG )PATTERN or any heart disease of mother or his fetus

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progress of labour | Cervical dilatation 1 cm / hour | up to 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Charcteristics of new_born | Apgar score at1minute and Apgar score at 5minutes | up to 1 month | 
| Time taken after ALERT EDT | Primgravida and Multipara | up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
WHO PARTOGRAPG.OBSTRUCTED LABOUR. managment of labour
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.

Official Title
-----------------
An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and DSM IV criteria. Subject's Mini-Mental Status Examination Score (MMSE) must be in the range of 13 - 25 (inclusive) at Screening. Exclusion Criteria: Subjects with dementia due to causes other than Alzheimer's disease. Any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet the objectives of the study.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atorvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| If the results of this study demonstrate efficacy and lead to the approval by the FDA of atorvastatin for use in humans for the treatment of Alzheimer's disease, this would be available as an additional treatment option for patients. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| If the results of this study demonstrate efficacy and lead to the approval by the Food and Drug Administration of atorvastatin for use in humans, subject activities of daily living are being assessed. |  |  |
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)

Study Overview
=================
Brief Summary
-----------------
This is a multicenter open-label phase II trial of high dose imatinib mesylate in patients with AML in first or second relapse, or with refractory disease. Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Response is assessed after 1, 2 and 3 months of treatment by bone marrow aspirate.

Detailed Description
-----------------
Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.

Official Title
-----------------
A Phase II Trial Evaluating the Safety and the Efficacy of High-Dose Imatinib in Relapsed/Refractory c-Kit Positive and BCR-Abl Negative AML Patients

Conditions
-----------------
AML

Intervention / Treatment
-----------------
* Drug: Imatinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years, AML in first or second relapse, refractory AML performance status of 0-2 on the Eastern Cooperative Oncology Group scale, adequate hepatic and renal functions (AST or ALT <= 5 times the upper limit of normal creatinine < 2 times the upper limit of normal) 20% blasts in bone marrow, 70% of bone marrow blast population c-kit positive as assessed by immunophenotyping Bcr-Abl negative chromosomal analysis (assessed by fluorescence in situ hybridization; FISH), and no chromosome 5-12 translocation Exclusion Criteria: Previous treatment by Imatinib Secondary AML

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |